8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 19, 2026·SEC
Skye Bioscience, Inc.(SKYE)Earnings, Financials & Key Ratios
SKYE•NASDAQ
$0.70
Price updated Jul 7, 2026
AboutSkye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.Show more
- Revenue$0
- EBITDA-$57M-92.1%
- Net Income-$56M-110.5%
- EPS (Diluted)-1.41-93.2%
- ROE-126.85%-57.6%
SKYE Price & Volume
Skye Bioscience, Inc. (SKYE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Capital Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- Skye Bioscience remains a high-risk, pre-revenue clinical-stage entity entirely dependent on external financing to advance its metabolic pipeline, specifically the Nimacimab program.
- The company's financial trajectory is characterized by aggressive capital consumption, with R&D expenses peaking at $14.3 million in 2025Q2, which continues to erode the equity base and total assets.
- Investors should monitor the critical liquidity risk, as the current cash balance of $8.1 million as of 2026Q1 appears insufficient to sustain long-term clinical trial operations without further dilutive capital raises.
Verdict Logic
the company faces imminent liquidity exhaustion with a cash position of only $8.1 million as of 2026Q1, which is inadequate to support the ongoing high-cost clinical development of its metabolic pipeline.
SKYE Growth Metrics
Skye Bioscience, Inc. (SKYE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-75.59%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-75.61%
Return on Capital
10 Years-652.22%
5 Years-758.77%
3 Years-781.81%
Last Year-131.39%
SKYE Recent Earnings
Skye Bioscience, Inc. (SKYE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.32-10.3%
$0.29
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.36-21.2%
$0.30
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.32+3.0%
$0.33
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.44-29.4%
$0.34
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.32vs $0.29-10.3% | — |
| Q2 2026 | Mar 10, 2026 | $0.36vs $0.30-21.2% | — |
| Q4 2025 | Nov 10, 2025 | $0.32vs $0.33+3.0% | — |
| Q3 2025 | Aug 7, 2025 | $0.44vs $0.34-29.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Skye Bioscience, Inc. (SKYE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.70 | $24.72M | -0.50 | — | — | -126.85% | — | |
| $5.19 | $1.91B | -1.78 | 1227.6% | -19019.44% | -366.21% | — | |
| $12.99 | $1.25B | -4.22 | — | — | -151.02% | — | |
| $20.69 | $2.04B | -10.04 | — | — | -102.48% | — | |
| $1.30 | $336.96M | -30.79 | 2.82% | -1.17% | -1% | — | |
| $9.38 | $117.58M | -1.59 | — | — | -70.89% | — |
Compare SKYE vs Peers
Skye Bioscience, Inc. (SKYE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SKYE SEC Filings & Documents
Skye Bioscience, Inc. (SKYE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SKYE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SKYE Frequently Asked Questions
Skye Bioscience, Inc. (SKYE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is SKYE profitable?
Skye Bioscience, Inc. (SKYE) reported a net loss of $57.3M for fiscal year 2025.
Dividend & Returns
What is SKYE's return on equity?
Skye Bioscience, Inc. (SKYE) has a return on equity (ROE) of -126.8%. Negative ROE indicates the company is unprofitable.
What is Skye Bioscience, Inc.'s free cash flow?
Skye Bioscience, Inc. (SKYE) had negative free cash flow of $42.4M in fiscal year 2025, likely due to heavy capital investments.